Dossier assessment
Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Axitinib for kidney cancer: hint of considerable added benefit
Compared with sorafenib, some side effects are less common in certain patients
Additional information
Federal Joint Committee (G-BA)
2013-03-21 A G-BA decision was published.
Project details
- Project no.
- A12-14
- Commission
- Commission awarded on 01.10.2012 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer, Kidneys and urinary system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed